Unique ID issued by UMIN | UMIN000045799 |
---|---|
Receipt number | R000052287 |
Scientific Title | Survey of clinical practice and prognostic factors for unresectable locally advanced pancreatic cancer: Multicenter prospective observational study |
Date of disclosure of the study information | 2021/10/20 |
Last modified on | 2022/11/10 01:38:36 |
Survey of clinical practice and prognostic factors for unresectable locally advanced pancreatic cancer: Multicenter prospective observational study
HOPS-UR02
Survey of clinical practice and prognostic factors for unresectable locally advanced pancreatic cancer: Multicenter prospective observational study
HOPS-UR02
Japan |
pancreatic cancer
Hepato-biliary-pancreatic medicine |
Malignancy
NO
Survey of clinical practice and prognostic factor for locally advanced unresectable pancreatic cancer
Safety,Efficacy
overall survival
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1. Unresectable locally advanced pancreatic cancer has been diagnosed by chest CT and abdominal contrast CT.
2. Invasive pancreatic ductal carcinoma (adenocarcinoma, adenosquamous carcinoma, mucinous carcinoma, anaplastic carcinoma) has been diagnosed by histological or cytological examination.
3. Distant metastasis corresponding to M1 is not found on the image.
d. First-line treatment (no history of treatment for pancreatic cancer).
e. The age of registration date is 20 years or older.
f. Written consent of the individual or his / her representative has been obtained for participation in the study.
1. Your physician determines that you are unsuitable for enrollment in the study.
2. Contrast-enhanced CT imaging is not possible due to drug allergy to iodine-based contrast media. However, contrast-enhanced CT imaging is not possible with steroid prophylactic administration.
3. Pleural effusion and ascites for which metastasis cannot be ruled out are observed on chest CT and abdominal / pelvic contrast CT.
4. Contrast-enhanced MRI shows a liver mass that metastasis cannot be ruled out.
5. Active double cancer (simultaneous double cancer). However, lesions such as carcinoma in situ or intramucosal cancer that are judged to be cured by topical therapy are not included in active double cancer.
130
1st name | Masaki |
Middle name | |
Last name | Kuwatani |
Hokkaido University Hospital
Department of Gastroenterology and Hepatology
060-8648
West 5, North 14, Kita-ku, Sapporo
011-716-1161
mkuwatan@med.hokudai.ac.jp
1st name | Makoto |
Middle name | |
Last name | Yoshida |
Sapporo Medical University Hospital
Department of clinical Oncology
060-8543
West 16, South 1, Chuo-Ku, Sapporo
011-611-2111
yoshimako10@sapmed.ac.jp
Hokkaido University Hospital
Hokkaido University Hospital
Self funding
Hokkaido University Certified Review Board
West 5, North 14, Kita-ku, Sapporo, Hokkaido
011-706-7934
recjimu@huhp.hokudai.ac.jp
NO
2021 | Year | 10 | Month | 20 | Day |
Unpublished
Enrolling by invitation
2021 | Year | 10 | Month | 01 | Day |
2021 | Year | 10 | Month | 28 | Day |
2021 | Year | 12 | Month | 01 | Day |
2029 | Year | 12 | Month | 31 | Day |
Each research director and research coordinator use the EDC (Electronic Data Capture) system "NorthNet" for researchers handled by the Clinical Research and Development Center of Hokkaido University Hospital using the Internet line. Accumulate. Collected data will be analyzed at the data management facility shown in the research implementationsystem.
2021 | Year | 10 | Month | 20 | Day |
2022 | Year | 11 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052287